Promising results of phase III trial for perampanel in epilepsy

Published: 2010-10-05

A novel investigational compound, generic name perampanel, has recently done well in an epilepsy trial. Discovered and developed by Eisai, perampanel is a first-in-class drug with a unique mechanism that selectively and non-competitively antagonises AMPA-type glutamate receptors. By preventing the excessive influx of calcium into brain cells, it suppresses the overactivity of excitatory nerves, thereby correcting excitatory-inhibitory nerve imbalance and inhibiting neuronal cell death.

The substance is being investigated as a potential treatment for epilepsy, neuropathic pain, multiple sclerosis and migraine prevention. Two further studies are under way, and if the results continue to be good, Eisai will apply for marketing authorisation in 2011. The most common adverse events reported were dizziness, somnolence and headache.

www.eisai.co.jp